412,565 Shares in Heartflow, Inc. $HTFL Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. bought a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 412,565 shares of the company’s stock, valued at approximately $13,887,000. JPMorgan Chase & Co. owned about 0.49% of Heartflow as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HTFL. Baillie Gifford & Co. purchased a new stake in Heartflow during the third quarter valued at about $101,182,000. New York State Common Retirement Fund acquired a new stake in shares of Heartflow during the third quarter valued at approximately $4,015,000. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Heartflow in the 3rd quarter valued at approximately $4,418,000. Board of Trustees of The Leland Stanford Junior University acquired a new position in Heartflow in the 3rd quarter worth approximately $10,510,000. Finally, Lisanti Capital Growth LLC purchased a new position in Heartflow during the 3rd quarter worth approximately $982,000.

Analysts Set New Price Targets

HTFL has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Stifel Nicolaus raised their price objective on Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Wells Fargo & Company assumed coverage on shares of Heartflow in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $38.00 price target for the company. Finally, Canaccord Genuity Group boosted their price objective on shares of Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.50.

Insiders Place Their Bets

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00. Following the completion of the sale, the insider directly owned 10,448,158 shares in the company, valued at $293,070,831.90. The trade was a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie A. Cullivan sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $27.32, for a total transaction of $218,560.00. Following the completion of the sale, the director directly owned 36,413 shares of the company’s stock, valued at $994,803.16. This represents a 18.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,095,715 shares of company stock worth $58,533,709 in the last quarter.

Heartflow Price Performance

Shares of NASDAQ HTFL opened at $23.93 on Thursday. Heartflow, Inc. has a one year low of $20.13 and a one year high of $41.22. The business’s 50-day moving average price is $28.68 and its two-hundred day moving average price is $31.05. The company has a market capitalization of $2.04 billion and a P/E ratio of -13.22.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.